MedTrace Logo

Study of Aranesp to Treat Anemia in Prostate Cancer Patients.

NCT00245895 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2007-11-29

No results posted yet for this study

Summary

The purpose of this study is to see if darbepoetin alfa is an effective treatment for anemia in prostate cancer patients and, if so, what dose is most effective. Sometimes prostate cancer patients have low red blood cell counts (low hemoglobin) from various treatments they are receiving, such as chemotherapy. The red blood cells deliver oxygen to the tissue. This then helps give the patient more energy.

Conditions

Interventions

DRUG

Aranesp

Aranesp

Sponsors & Collaborators

Principal Investigators

  • Celestia S Higano, MD · University of Washington

  • Tomasz M Beer, MD · Oregon Health and Science University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Completion
2005-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00245895 on ClinicalTrials.gov